Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Visium Asset Management Has Nearly Doubled Its Stake in La Jolla Pharmaceutical Co (LJPC)

Page 1 of 12

We are seeing a boatload of 13G filing activity at the moment and investment firms disclose their positions as of the end of 2015 (we are not publishing these filings, as they are outdated). One of the more noteworthy relevant filings is this one submitted to the SEC by Jacob Gottlieb‘s Visium Asset Management. This filing details the investor’s updated position in La Jolla Pharmaceutical Company (NASDAQ:LJPC), including the fact that it now holds 1.18 million shares of the company (you can see these figures in the table below), nearly double the 630,000 shares that Visium reported holding as of the end of September. Given the investor’s prominent position in the stock, we recommend paying close attention to the details in the following filing if you’re considering how to trade the company’s stock right now.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Visium Balanced Master Fund, Ltd. 1,182,013 1,182,013 1,182,013 6.5%
Visium Asset Management, 1,182,013 1,182,013 1,182,013 6.5%
JG Asset, 1,182,013 1,182,013 1,182,013 6.5%
Jacob Gottlieb 1,182,013 1,182,013 1,182,013 6.5%
Jacob Gottlieb
Jacob Gottlieb
Visium Asset Management

Page 1 of 12 SEC Filing

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

 

 

La Jolla
Pharmaceutical Company

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

503459604

(CUSIP Number)

January 28, 2016

(Date of Event Which Requires Filing of this Statement)

 

 

Check the
appropriate box to designate the rule pursuant to which this Schedule is filed:

x Rule
13d-1(b)**

x Rule 13d-1(c)**

¨ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.
** This Schedule is being filed pursuant to Rule 13d-1(b) with respect to Visium Asset Management, LP, JG Asset, LLC and Jacob Gottlieb, and pursuant to Rule 13d1-(c) with respect to Visium Balanced Master Fund, Ltd.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of
the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow La Jolla Pharmaceutical Co (NASDAQ:LJPC)
Trade (NASDAQ:LJPC) Now!
Page 1 of 12

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!